Studies have shown that increased serum TGF-β levels are associated with ovarian cancer metastasis and drug resistance, and that dnTGFβRII helps CAR T cells resist the immunosuppressive effect of TGF-β [26, 27]. Here, TGFB1 is linked to ovarian carcinoma.